Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure
Authors:
- 1 May 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 179 (5) , 1768-1774
Abstract
Purpose: We evaluate the usefulness of pretreatment 111Indium capromab pendetide (ProstaScint™) planar imaging (immunoscintigraphy) plus single photon emission tomography co-registration with computerized tomography scans to detect occult metastatic disease and predict for biochemical failure, in a cohort of patients with a clinical diagnosis of localized adenocarcinoma of the prostate referred for primary radiotherapy. Materials and Methods: Patients were followed after radiotherapy for evidence of biochemical failure using 2 criteria of prostate specific antigen clinical nadir +2 ng/ml and American Society for Therapeutic Radiology and Oncology Consensus definitions. Median followup was 58.8 months (mean 64.8). Clinical risk factors defined 3 risk groups of high (51), intermediate (72) and low (116). Results: Overall biochemical failure was 18.3% vs 11.8% by the 2-BFC at 8-year actuarial analysis with 58.8 months median followup. By the CN +2 definition the control date for the cohort is 34.8 months. Pretreatment SPECT/CT suggested prostate cancer metastasis (22), seminal vesicle extension (20) and organ confined disease (197). Biochemical failure in patients having extra-periprostatic metastatic prostate cancer, seminal vesicle extension and organ confined disease uptake on SPECT/CT was 43.2%, 16.0% vs 14.7% (p = 0.0006); and 33.3%, 15.0% vs 8.7% (p = 0.0017) by the 2-BFC, respectively. Cox multiple regression analysis demonstrated that a finding of extra-periprostatic metastatic prostate on SPECT/CT significantly predicted a 4.2-fold greater risk (p = 0.0012) and a 4.5-fold greater risk (p = 0.0011) of failure by the 2-BFC than organ confined disease adjusting for treatment and risk group. Conclusions: Unconfirmed findings of extra-periprostatic metastatic prostate cancer on SPECT/CT immunoscintigraphy independently and significantly predicted an increased risk of biochemical failure in patients presenting for radiotherapy with a clinical diagnosis of localized prostate cancer.Keywords
This publication has 12 references indexed in Scilit:
- Guideline for the Management of Clinically Localized Prostate Cancer: 2007 UpdateJournal of Urology, 2007
- Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetideBrachytherapy, 2007
- Cumulative cost pattern comparison of prostate cancer treatmentsCancer, 2006
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planningInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate CancerNew England Journal of Medicine, 2003
- Multicenter ProstaScint imaging findings in 2154 patients with prostate cancerUrology, 2000
- Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 Interstitial Sources: Dosimetry and calibration changes: Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc SubcommitteeMedical Physics, 1999
- Review of AAPM task group no. 43 recommendations on interstitial brachytherapy sources dosimetryMedical Dosimetry, 1998